INDEMNIFICATION AGREEMENTIndemnification Agreement • January 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 2013 between Dance Biopharm Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • California
EMPLOYMENT AGREEMENTEmployment Agreement • May 21st, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (this “Agreement”), dated May 17, 2014 and effective on the date of consummation of the initial public offering of the Company’s common stock (the “Effective Date”), is by and between DANCE BIOPHARM INC., a Delaware corporation (the “Company”) and LISA E. PORTER, M.D. (the “Executive”).
CONFIDENTIAL LICENSE, DEVELOPMENT, COLLABORATION, AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN DANCE PHARMACEUTICALS, INC. AND AEROGEN LIMITED NOVEMBER 2010And Commercialization Agreement • May 21st, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • New York
MASTER MANUFACTURING AGREEMENT For Medical Products / Finished Device Assembly [*] Insulin InhalerMaster Manufacturing Agreement • May 21st, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • New York
This MASTER MANUFACTURING AGREEMENT (the “Agreement”) is entered into this 25th day of November, 2013 (the “Effective Date”) between Dance Biopharm Inc. (“Buyer”), a Delaware corporation, having an office located at 2 Mint Plaza #804, San Francisco, CA 94103, and Phillips Plastics Corporation (“Seller”), a Wisconsin corporation, having its headquarters at 1201 Hanley Road, Hudson, WI 54016. Buyer and Seller may sometimes be referred to individually as a (“Party”) or collectively as the (“Parties”).
DANCE PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKDance Biopharm, Inc. • January 9th, 2014 • Pharmaceutical preparations • Delaware
The undersigned acknowledges that he, she or it has reviewed the representations and warranties contained in Annex 1 hereto and by his, her or its signature below hereby makes such representations and warranties to the Company. The undersigned further acknowledges that he, she or it, as a condition to the purchase of Warrant Shares, he, she or it, shall execute a counterpart signature page to each applicable Stockholder Agreement and be bound by the terms set forth therein.
ContractLicense, Supply and Manufatcuring Agreement • April 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • England
[*Confidential Treatment has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately with the Securities and Exchange Commission.]
PHASE 3 CLINICAL and COMMERCIAL SUPPLY AGREEMENT (STERILE PUMPS)Manufacturing and Supply Agreement • April 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • London
THIS SUPPLY AGREEMENT (this “Agreement”) is effective as of March 24, 2014 (the “Effective Date”) and is between Dance Biopharm Inc., a company organized under the laws of Delaware, with principal offices at 150 North Hill Drive #24, Brisbane, California 94103 (“DANCE”), AERO PUMP GmbH organized under the laws of Germany,with principle office located in Dr.-Ruben-Rausing-StraBe. 5 65239 Hochheim/Main (“AERO PUMP”) AERO PUMP subsidiary URSATEC Verpackung-GmbH, organized under the laws of Germany, with principal office located at SchillerstraBe 4 66606 St. Wendel (“URSATEC”) and any other AERO PUMP subsidiary or associated company.
MANUFACTURING AGREEMENTManufacturing Agreement • April 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations
THIS MANUFACTURING AGREEMENT (this “Agreement”) is made and entered into effective as of the 6th day of March, 2014 (the “Effective Date”) by and between Dance Biopharm Inc., a Delaware corporation having a place of business at 150 North Hill Drive, Suite 24, Brisbane, California 94005, USA (“Dance”) and Rechon Life Science AB, a Swedish company having a place of business at Soldattorpsvägen 5, 216 10 Limhamn, Sweden (“Rechon”).
OFFICE LEASE (GROSS)Lease Agreement • April 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • California
THIS LEASE is dated as of December 16, 2013 (“Effective Date”), and is entered into by and between WVP Bay Tech, LLC, a California limited liability company (“Landlord”), and Dance Biopharm, Inc., a Delaware corporation (“Tenant”). In consideration of the mutual covenants and agreements contained herein, the parties agree as follows:
SUPPLY AGREEMENT (RECOMBINANT HUMAN INSULIN)Manufacturing and Supply Agreement • April 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • London
THIS SUPPLY AGREEMENT (this “Agreement”) is effective as of March 25, 2014 (the “Effective Date”) and is between Dance Biopharm Inc., a company organized under the laws of Delaware, with principal offices at 150 North hill Drive, Brisbane, California 94005, USA (“DANCE”) and Tonghua Dongbao Pharmaceuticals Co., Ltd., organized under the Peoples Republic of China, with principle office located in Tonghua City Jilin Province, China (“DONGBAO”).
ContractWarrant Agreement • April 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • California
THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.
AMENDMENT TO DANCE BIOPHARM INC. Dated: December 10, 2013Equity Incentive • January 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations
This Agreement amends the Dance Biopharm Inc. (formerly known as Dance Pharmaceuticals, Inc.) 2009 Equity Incentive Plan (the “Plan”). All capitalized terms not defined herein shall have the meanings set forth in the Plan.
SUPPLY AGREEMENT (RECOMBINANT HUMAN INSULIN)Manufacturing and Supply Agreement • March 5th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations • London
THIS SUPPLY AGREEMENT (this “Agreement”) is effective as of January 15, 2014 (the “Effective Date”) and is between Dance Biopharm Inc., a company organized under the laws of Delaware, with principal offices at 2 Mint Plaza #804, San Francisco, California 94103 (“DANCE”) and Gulf Pharmaceutical Industries organized under the laws UAE, with principle office located in Digdaga, Airport Road, Ras Al Khaimah, UAE , PO BOX 997 (“JULPHAR”).
MASTER AGREEMENT FOR JOINT VENTURE IN ASIADance Biopharm, Inc. • January 9th, 2014 • Pharmaceutical preparations • Hong Kong
This Master Agreement for a Joint Venture in Asia (“Agreement”) is made and entered into as of February 20, 2013, by and between Dance Biopharm Inc., a Delaware corporation, having its principal offices at 2 Mint Plaza #804, San Francisco, California 94103 (“Dance”) and Harmony Plus Holdings Limited, a Hong Kong corporation, having its principal offices at Room 1902, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong (“Harmony”). Dance and Harmony are together referred to herein as the “Parties” and each is variously referred to as a “Party”.
Dance Biopharm Inc. San Francisco, CA 94103Dance Biopharm, Inc. • April 9th, 2014 • Pharmaceutical preparations
This Lease is made effective the 1st day of May 2013 by and between John Patton (hereinafter “Landlord”) and Dance Biopharm Inc. (hereinafter “Tenant”). In consideration for the mutual promises and covenants contained herein, and for other good and valuable consideration, the parties hereby agree as follows:
ADDENDUM 1 to the License, Development, Collaboration and Commercialization Agreement COMMERCIAL SUPPLY AGREEMENT FOR DEVICE PROPRIETARY COMPONENTSLicence Agreement • January 9th, 2014 • Dance Biopharm, Inc. • Pharmaceutical preparations
This Addendum 1 (the “Addendum”, which expression includes any Appendices hereto) is to the LICENSE, DEVELOPMENT, COLLABORATION AND COMMERCIALIZATION AGREEMENT (the “License Agreement”) by and between Aerogen Limited, a private limited company incorporated in Ireland having its principal place of business at Galway Business Park, Dangan, Galway, Ireland (“Aerogen”) and Dance Biopharm, Inc., a Delaware, USA corporation having its principal place of business at 2 Mint Plaza, Suite 804, San Francisco, CA 94103, USA (“Dance”) (individually, a “Party” and jointly, “the Parties”) with an Effective Date of the 15th day of November, 2010. The effective date of this Addendum is 4th October, 2013 (the “Addendum Effective Date.”)
